| Literature DB >> 35919347 |
Augustin Coisne1, Victor Fourdinier1, Gilles Lemesle2, Pascal Delsart1, Samy Aghezzaf1, Nicolas Lamblin3, Guillaume Schurtz2, Basile Verdier2, Sandro Ninni1, Antoine Delobelle1, Francesco Favata1, Camille Garret1, Claire Seunes1, Amandine Coppin1, Erwan Donal4, Andrea Scotti5, Azeem Latib6, Juan F Granada5, Christophe Bauters3, David Montaigne1.
Abstract
Aims: To investigate the additional prognostic value of myocardial work (MW) parameters following acute myocardial infarction (AMI). Methods and results: Between 2018 and 2020, 244 patients admitted in the cardiac intensive care unit in Lille University Hospital for AMI were included. One-month following AMI, comprehensive transthoracic echocardiography (TTE) was performed to assess parameters of myocardial function. Patients were then followed for major events (ME): cardiovascular death, heart failure, and unplanned coronary revascularization. At 1-month, half of the population was symptomatic (NYHA ≥ II), and medical therapy was almost optimized (angiotensin-converting enzyme inhibitor/angiotensin 2 receptor blocker in 95.5%, beta-blockers in 96.3%, DAPT in 94.7%, and statins in 97.1%). After a median follow-up of 681 (interquartile range: 538-840) days, ME occurred in 26 patients (10.7%). Patients presenting ME were older (65.5 ± 14.2 vs. 58.1 ± 12.1years, P = 0.005) with a higher prevalence of hypertension (65.4 vs. 36.2%, P = 0.004), more impaired left ventricular (LV) function as assessed by LV ejection fraction (P = 0.07), global longitudinal strain (P = 0.03), or MW parameters [P = 0.01 for global work efficiency (GWE)], and greater LV and left atrium dilatations (P = 0.06 for left ventricular end-diastolic volume index and P = 0.03 for left atrial volume index). After adjustment, GWE was the only TTE parameter independently associated with long-term occurrence of ME (P = 0.02). A GWE value <91% was selected to identify patients at higher ME risk (hazard ratio: 95% confidence interval) = 2.94 (1.36-6.35), P = 0.0041).Entities:
Keywords: Global work efficiency; Myocardial infarction; Myocardial work
Year: 2022 PMID: 35919347 PMCID: PMC9242079 DOI: 10.1093/ehjopen/oeac037
Source DB: PubMed Journal: Eur Heart J Open ISSN: 2752-4191
Baseline characteristics at acute myocardial infarction admission
| All patients | No ME | ME | ||
|---|---|---|---|---|
| Age (years) | 58.8 ± 12.6 | 58.1 ± 12.1 | 65.5 ± 14.2 | 0.005 |
| Gender women | 51 (20.9) | 45 (20.6) | 6 (23.1) | 0.77 |
| BMI (kg/m2) | 27.4 ± 4.5 | 26.9 ± 5.5 | 27.3 ± 732 | 0.70 |
| Diabetes mellitus | 31 (12.7) | 26 (11.9) | 5 (19.2) | 0.29 |
| Hypertension | 96 (39.3) | 79 (36.2) | 17 (65.4) | 0.004 |
| Active smoking | 175 (71.7) | 156 (71.6) | 19 (73.1) | 0.87 |
| Stroke | 6 (2.5) | 4 (1.8) | 2 (7.7) | 0.07 |
| ST elevation MI | 173 (70.9) | 158 (72.5) | 15 (57.7) | 0.12 |
| Chronic kidney disease | 6 (2.5) | 6 (2.8) | 0 (0) | 0.39 |
| Killlip Class | 0.03 | |||
| I | 213 (87.0) | 195 (89.4) | 18 (69.2) | |
| II | 3 (1.2) | 2 (0.9) | 1 (3.8) | |
| III | 5 (2.0) | 1 (0.5) | 4 (15.4) | |
| IV | 23 (9.4) | 20 (9.2) | 3 (11.5) | |
| Haemoglobin (g/dL) | 14.3 (13.2; 15.3) | 14.4 (13.4; 15.3) | 13.5 (12.7; 15.0) | 0.05 |
| Creatinine (mg/L) | 9 (7–10) | 9 (7–10) | 9 (8–12) | 0.03 |
| Troponin T hs peak (ng/L) | 2016 (669; 4786) | 2119 (687; 4828) | 820 (491; 3604) | 0.25 |
| LVEF (%) | 50.4 ± 10.7 | 50.7 ± 10.5 | 47.7 ± 12.1 | 0.17 |
| LV dilatation | 19 (7.8) | 16 (7.3) | 3 (11.5) | 0.46 |
| Wall motion abnormality | 185 (75.8) | 165 (75.7) | 20 (76.9) | 0.92 |
| Hospitalization length (days) | 6.7 ± 4.1 | 6.7 ± 4.2 | 6.7 ± 2.8 | 0.99 |
Data are mean ± SD, median (interquartile) or n (%). BMI, body mass index; LV, left ventricle; ME, major event; MI, myocardial infarction.
One-month evaluation after myocardial infarction
| All Patients | No ME | ME | ||
|---|---|---|---|---|
| NYHA Class | 0.07 | |||
| I | 124 (50.8) | 112 (51.6) | 12 (46.2) | |
| II | 71 (29.1) | 67 (30.7) | 4 (15.4) | |
| III | 43 (17.6) | 35 (16.1) | 8 (30.8) | |
| IV | 6 (2.5) | 4 (1.8) | 2 (7.7) | |
| SBP (mmHg) | 127.3 ± 20.8 | 127.5 ± 20.8.5 | 126.3 ± 20.9 | 0.79 |
| Heart rate (bpm) | 63.3 ± 123 | 63.0 ± 12.1 | 66.2 ± 13.7 | 0.21 |
| LVEF (%) | 54.4 ± 8.8 | 54.8 ± 8.5 | 51.4 ± 10.8 | 0.07 |
| GLS (%) * | 15.8 ± 3.7 | 16.0 ± 3.5 | 14.3 ± 4.6 | 0.03 |
| GWI (mmHg%) | 1731 ± 509 | 1751 ± 488 | 1563 ± 648 | 0.08 |
| GCW (mmHg%) | 1844 ± 510 | 1863 ± 494 | 1685 ± 617 | 0.09 |
| GWW (mmHg%) | 131 ± 73 | 130 ± 72 | 144 ± 74 | 0.33 |
| GWE (%) | 91.2 ± 6.6 | 91.6 ± 6.1 | 88.1 ± 9.3 | 0.01 |
| LVEDVi (mL/m2) | 65.1 ± 14.8 | 64.4 ± 14.4 | 70.2 ± 16.8 | 0.06 |
| LVESVi (mL/m2) | 29.2 ± 12.5 | 28.5 ± 11.8 | 34.4 ± 16.6 | 0.02 |
| LA volume (mL/m2) | 37.7 ± 10.4 | 37.2 ± 10.1 | 42.1 ± 12.0 | 0.03 |
| TR velocity (m/s) | 2.59 ± 0.35 | 2.59 ± 0.35 | 2.56 ± 0.34 | 0.79 |
| E/e' | 8.8 ± 3.4 | 8.6 ± 3.3 | 10.1 ± 4.1 | 0.04 |
| TAPSE (mm) | 23.3 ± 4.4 | 23.3 ± 4.5 | 23.5 ± 4.2 | 0.82 |
| ACEi or ARB | 233 (95.5) | 210 (96.3) | 23 (88.5) | 0.07 |
| MRA | 31 (12.8) | 26 (12.0) | 5 (19.2) | 0.30 |
| Beta-blockers | 235 (96.3) | 211 (96.8) | 24 (92.3) | 0.25 |
| Statins | 237 (97.1) | 211 (96.8) | 26 (100) | 0.35 |
| Dual antiplatelet therapy | 236 (94.7) | 210 (96.3) | 26 (100) | 0.32 |
| Anticoagulant | 21 (8.6) | 18 (8.3) | 3 (11.5) | 0.63 |
Data are mean ± SD, median (interquartile) or n (%). ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin 2 receptor blocker; GCW, global constructive work; GWE, global work efficiency; GWI, global work index; GWW, global wasted work; LA volume, left atrium volume; LVEF, left ventricular ejection fraction; LVEDVi, indexed left ventricular end-diastolic volume; LVESVi, indexed left ventricular end-systolic; ME, major event; MRA, mineralocorticoid receptor blocker; NYHA, New York Heart Association; SBP, systolic blood pressure; TR, tricuspid regurgitation. * absolute value
Cox regression analyses to assess determinants of major events following myocardial infarction
| Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|
|
| HR (95% CI) | β ± SE |
| HR (95% CI) | β ± SE | |
| Age | 0.0046 | 0.04 ± 0.02 | - | - | - | |
| Hypertension | 0.006 | 3.12 (1.39–7.01) | 0.02 | 2.72 (1.20–6.19) | ||
| Stroke | 0.06 | 4.05 (0.95–17.5) | 0.04 | 5.63 (1.28–24.7) | ||
| Killip Class | 0.03 | 1.42 (1.04–1.93) | 0.04 | 1.41 (1.01–1.96) | - | |
| NYHA Class | 0.06 | 1.51 (0.99–2.31) | - | - | - | |
| LVEF (%) | 0.05 | −0.04 ± 0.02 | - | - | - | |
| GLS (%) * | 0.017 | −0.12 ± 0.05 | - | - | - | |
| GWI (mmHg%) | 0.049 | −0.0008 ± 0.0004 | - | - | - | |
| GCW (mmHg%) | 0.07 | −0.0007 ± 0.0004 | - | - | - | |
| GWE (%) | 0.006 | −0.05 ± 0.02 | 0.02 | −0.05 ± 0.02 | ||
| LVEDVi (mL/m2) | 0.048 | 0.02 ± 0.01 | - | - | - | |
| LVESVi (mL/m2) | 0.015 | 0.03 ± 0.01 | - | - | - | |
| LA volume (mL/m2) | 0.02 | 0.04 ± 0.02 | - | - | - | |
| E/e' | 0.03 | 0.07 ± 0.03 | - | - | - | |
| ACEi or ARB | 0.08 | 0.35 (0.10–1.15) | - | - | - | |
| Haemoglobin (g/dL) | 0.007 | −0.23 ± 0.09 | - | - | - | |
Data are mean ± SD, median (interquartile) or n (%). ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin 2 receptor blocker; GCW, global constructive work; GWE, global work efficiency; GWI, global work index; LA volume, left atrium volume; LVEF, left ventricular ejection fraction; LVEDVi, indexed left ventricular end-diastolic volume; LVESVi, indexed left ventricular end-systolic; ME, major event; NYHA, New York Heart Association. * absolute value. P value by Cox-proportional hazards regression stepwise model